BioWorld tracked 260 clinical trial readouts across phases I through III in June 2026, compared to 262 in May. By phase, BioWorld recorded 87 phase I readouts in May, 90 in phase II and 83 in phase III, a relatively even spread across phases. Of the phase III programs, 32 trials posted positive results, and five failed to meet primary endpoints.

Med-tech deal value, covering licensing agreements, joint ventures and development collaborations, through the first half (H1) of 2026 reached $5.28 billion, the second-highest H1 total behind 2023’s $6.88 billion.

Biopharma deal value through the first half (H1) of 2026 totaled $170.11 billion, the highest H1 total in BioWorld’s records by a wide margin and a 22% increase from H1 2025’s $139.35 billion, the previous record high. Both quarters were strong, with the first quarter (Q1) contributing $79.71 billion and Q2 jumping to $90.4 billion, the highest single quarter on record after edging past Q4 2024’s $80.65 billion.

Total med-tech financing through the first half (H1) of 2026 reached $12.66 billion, down from 2025’s $17.56 billion but in line with 2024’s $13.94 billion over the same period.

Global drug approvals through the first half (H1) of 2026 reached 261, the third-highest H1 total in BioWorld’s records behind 2021’s 288 and 2025's 271, and ahead of 2022’s 256. June was the standout month of the first six months at 64 approvals, the highest single month in BioWorld’s records and a notable acceleration from May’s 43.

Global drug approvals through the first half (H1) of 2026 reached 261, the third-highest H1 total in BioWorld’s records behind 2021’s 288 and 2025's 271, and ahead of 2022’s 256. June was the standout month of the first six months at 64 approvals, the highest single month in BioWorld’s records and a notable acceleration from May’s 43.

Total med-tech financing through the first half (H1) of 2026 reached $12.66 billion, down from 2025’s $17.56 billion but in line with 2024’s $13.94 billion over the same period.

Biopharma financing activity through the first two quarters of 2026 totaled $60.14 billion, the strongest first-half (H1) showing since 2024’s $70.32 billion and well above 2025’s $29.53 billion over the same period. The second quarter (Q2) of 2026 was particularly strong at $34.69 billion, the highest single quarter since Q1 2024’s $47.25 billion. Q1 came in at $25.45 billion, more than double 2025’s Q1 figure of $13.12 billion.

Biopharma deal value through the first half (H1) of 2026 reached $170.11 billion, surpassing every prior year in BioWorld’s records, including 2025’s $139.35 billion, the previous high-water mark. June was the second-strongest month of H1 at $34.59 billion, trailing only May’s $41.95 billion.

Biopharma deal value through the first half (H1) of 2026 reached $170.11 billion, surpassing every prior year in BioWorld’s records, including 2025’s $139.35 billion, the previous high-water mark. June was the second-strongest month of H1 at $34.59 billion, trailing only May’s $41.95 billion.